172 related articles for article (PubMed ID: 18421166)
1. Complex of human neutrophil elastase with 1/2SLPI.
Koizumi M; Fujino A; Fukushima K; Kamimura T; Takimoto-Kamimura M
J Synchrotron Radiat; 2008 May; 15(Pt 3):308-11. PubMed ID: 18421166
[TBL] [Abstract][Full Text] [Related]
2. Structure basis 1/2SLPI and porcine pancreas trypsin interaction.
Fukushima K; Kamimura T; Takimoto-Kamimura M
J Synchrotron Radiat; 2013 Nov; 20(Pt 6):943-7. PubMed ID: 24121345
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of an elastase-specific inhibitor elafin complexed with porcine pancreatic elastase determined at 1.9 A resolution.
Tsunemi M; Matsuura Y; Sakakibara S; Katsube Y
Biochemistry; 1996 Sep; 35(36):11570-6. PubMed ID: 8794736
[TBL] [Abstract][Full Text] [Related]
4. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases.
Zani ML; Baranger K; Guyot N; Dallet-Choisy S; Moreau T
Protein Sci; 2009 Mar; 18(3):579-94. PubMed ID: 19241385
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of murine neutrophil serine proteinases by human and murine secretory leukocyte protease inhibitor.
Wright CD; Kennedy JA; Zitnik RJ; Kashem MA
Biochem Biophys Res Commun; 1999 Jan; 254(3):614-7. PubMed ID: 9920787
[TBL] [Abstract][Full Text] [Related]
6. Secretory leukocyte protease inhibitor (SLPI) is, like its homologue trappin-2 (pre-elafin), a transglutaminase substrate.
Baranger K; Zani ML; Labas V; Dallet-Choisy S; Moreau T
PLoS One; 2011; 6(6):e20976. PubMed ID: 21687692
[TBL] [Abstract][Full Text] [Related]
7. Specific cleavage of secretory leukoprotease inhibitor by neutrophil elastase and saliva.
Masuda K; Suga T; Takeuchi A; Kanesaki M; Imaizumi A; Suzuki Y
Biochem Pharmacol; 1994 Aug; 48(4):651-7. PubMed ID: 8080437
[TBL] [Abstract][Full Text] [Related]
8. Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cells.
Abbinante-Nissen JM; Simpson LG; Leikauf GD
Am J Physiol; 1993 Sep; 265(3 Pt 1):L286-92. PubMed ID: 8105697
[TBL] [Abstract][Full Text] [Related]
9. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function.
Yang J; Zhu J; Sun D; Ding A
Biochim Biophys Acta; 2005 Sep; 1745(3):310-7. PubMed ID: 16112212
[TBL] [Abstract][Full Text] [Related]
10. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease.
Schmid M; Fellermann K; Fritz P; Wiedow O; Stange EF; Wehkamp J
J Leukoc Biol; 2007 Apr; 81(4):907-15. PubMed ID: 17200145
[TBL] [Abstract][Full Text] [Related]
11. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family.
Moreau T; Baranger K; Dadé S; Dallet-Choisy S; Guyot N; Zani ML
Biochimie; 2008 Feb; 90(2):284-95. PubMed ID: 17964057
[TBL] [Abstract][Full Text] [Related]
12. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.
Weldon S; McNally P; McElvaney NG; Elborn JS; McAuley DF; Wartelle J; Belaaouaj A; Levine RL; Taggart CC
J Immunol; 2009 Dec; 183(12):8148-56. PubMed ID: 20007580
[TBL] [Abstract][Full Text] [Related]
13. Inhibition by recombinant SLPI and half-SLPI (Asn55-Ala107) of elastase and cathepsin G activities: consequence for neutrophil-platelet cooperation.
Renesto P; Balloy V; Kamimura T; Masuda K; Imaizumi A; Chignard M
Br J Pharmacol; 1993 Apr; 108(4):1100-6. PubMed ID: 8097952
[TBL] [Abstract][Full Text] [Related]
14. Location of the protease-inhibitory region of secretory leukocyte protease inhibitor.
Eisenberg SP; Hale KK; Heimdal P; Thompson RC
J Biol Chem; 1990 May; 265(14):7976-81. PubMed ID: 2110563
[TBL] [Abstract][Full Text] [Related]
15. Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase.
van Wetering S; van der Linden AC; van Sterkenburg MA; Rabe KF; Schalkwijk J; Hiemstra PS
J Investig Med; 2000 Sep; 48(5):359-66. PubMed ID: 10979241
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological activity of the C-terminal and N-terminal domains of secretory leukoprotease inhibitor in vitro.
Masuda K; Kamimura T; Watanabe K; Suga T; Kanesaki M; Takeuchi A; Imaizumi A; Suzuki Y
Br J Pharmacol; 1995 Jul; 115(6):883-8. PubMed ID: 7582515
[TBL] [Abstract][Full Text] [Related]
17. Release of neutrophil proteinase 4(3) and leukocyte elastase during phagocytosis and their interaction with proteinase inhibitors.
Bergenfeldt M; Axelsson L; Ohlsson K
Scand J Clin Lab Invest; 1992 Dec; 52(8):823-9. PubMed ID: 1362620
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription.
McNeely TB; Shugars DC; Rosendahl M; Tucker C; Eisenberg SP; Wahl SM
Blood; 1997 Aug; 90(3):1141-9. PubMed ID: 9242546
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil elastase reduces secretion of secretory leukoproteinase inhibitor (SLPI) by lung epithelial cells: role of charge of the proteinase-inhibitor complex.
Sullivan AL; Dafforn T; Hiemstra PS; Stockley RA
Respir Res; 2008 Aug; 9(1):60. PubMed ID: 18699987
[TBL] [Abstract][Full Text] [Related]
20. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes.
Sallenave JM; Shulmann J; Crossley J; Jordana M; Gauldie J
Am J Respir Cell Mol Biol; 1994 Dec; 11(6):733-41. PubMed ID: 7946401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
